+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P05886(IL6R Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Interleukin-6 receptor (IL6R) antibodies are therapeutic agents targeting the IL-6 signaling pathway, which plays a central role in inflammation, immune responses, and hematopoiesis. IL-6 binds to membrane-bound or soluble IL6R, forming a complex that activates gp130 receptors, triggering pro-inflammatory signaling via JAK/STAT and other pathways. Dysregulated IL-6 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), cytokine release syndrome (CRS), and certain cancers.

IL6R antibodies, such as tocilizumab and sarilumab, block IL-6 binding to its receptor, inhibiting both classical signaling (membrane IL6R) and trans-signaling (soluble IL6R). Approved for rheumatoid arthritis, juvenile idiopathic arthritis, and CRS (e.g., in severe COVID-19 or CAR-T therapy), these monoclonal antibodies reduce inflammation and tissue damage. Siltuximab, another IL6R antibody, targets IL-6 directly and is used for multicentric Castleman’s disease.

Research continues to explore their efficacy in other conditions, including atherosclerosis and neurodegenerative diseases. However, long-term IL-6 inhibition may increase infection risks, necessitating careful clinical monitoring. Emerging strategies include engineered antibodies with improved specificity or dual targeting of IL-6-related pathways. IL6R antibodies exemplify the therapeutic potential of cytokine modulation in immune-mediated disorders.